Physician profile
Jason Bundy
NPI 1164644548
$7,708.96
in general payments reported to CMS, 2019-2025
30 companies · $968 in 2025
The $968 reported for 2025 was more than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $601 · 2020: $490 · 2021: $998 · 2022: $1,209 · 2023: $1,245 · 2024: $2,198 · 2025: $968.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,411.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,411.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $3,185.59 | 2019-2025 | Proclaim, Eterna |
| Medtronic, INC. | $1,435.41 | 2021-2025 | Intellis Adaptivestim |
| Boston Scientific Corporation | $503.61 | 2019-2024 | Wavewriter Alpha Prime 16, Patient Trial Kit |
| Medtronic USA, INC. | $429.41 | 2019-2020 | |
| Pfizer INC. | $254.16 | 2019-2020 | |
| Relievant Medsystems, INC. | $157.16 | 2022-2023 | Intracept |
| Collegium Pharmaceutical, INC. | $157.16 | 2023-2024 | Belbuca, Xtampza |
| Biotronik Nro, INC. | $153.97 | 2023-2025 | Prospera, Biotronik |
| Mml US, INC. | $152.93 | 2022-2023 | Reactiv8 |
| Scilex Pharmaceuticals INC. | $136.10 | 2020-2023 | Ztlido |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $116.47 | 2023-2024 | Relistor |
| Astrazeneca Pharmaceuticals LP | $100.25 | 2023-2024 | Wainua |
| Abbvie INC. | $92.69 | 2023-2024 | Qulipta |
| Ibsa Pharma INC. | $86.89 | 2021-2024 | Tirosint, Licart, Licart |
| Nevro Corp. | $84.75 | 2020-2023 | Senza |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Appliedvr INC | $77.14 | 2025 | Relievrx |
| Biodelivery Sciences International, INC. | $71.58 | 2021 | |
| Bioventus LLC | $60.78 | 2021-2022 | |
| Si-Bone, INC. | $57.10 | 2019-2024 | |
| Vertex Pharmaceuticals Incorporated | $50.48 | 2024-2025 | |
| Avanos Medical | $46.70 | 2025 | Generator |
| Nalu Medical, INC. | $44.13 | 2022-2024 | Nalu Neurostimulation System |
| Stryker Corporation | $43.85 | 2024 | Mild Device Kit |
| Electronic Waveform Lab, INC. | $43.73 | 2019-2021 | |
| Almatica Pharma LLC | $43.34 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $42.12 | 2022 | |
| International Rehabilitative Sciences, INC | $39.75 | 2023 | Rs 4i Plus Sequential Stimulator |
| Saluda Medical Americas, INC. | $19.10 | 2025 | Evoke |
| Forte Bio-Pharma LLC | $11.79 | 2021 | |
| Vertical Pharmaceuticals, LLC | $10.82 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Bundy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.